Back

NewroBus for the brain: humanized TfR1-targeting nanobodies with high BBB permeability and cargo transport capacity

Yin, T.; Yesiltepe, M.; Metkar, S.; Ramon, A. E.; Greening, M.; Sormanni, P.; D'Adamio, L.

2025-04-24 bioengineering
10.1101/2025.04.20.649139 bioRxiv
Show abstract

Effective delivery of therapeutics to the brain is restricted by the blood-brain barrier (BBB). A strategy to overcome this limitation involves taking advantage of receptor-mediated transcytosis pathways, such as those mediated by transferrin receptor 1 (TfR1), which is highly expressed on brain endothelial cells and naturally transports iron-bound transferrin across the BBB. To exploit this mechanism, we immunized camelids with human TfR1 and cloned 470 VHH nanobody sequences from their B cells. From this repertoire, 24 nanobodies (TfR1b-Nbs) were identified that bind human TfR1 on the cell membrane. These nanobodies were screened for binding to human TfR1, lack of interference with transferrin binding and TfR1-mediated iron uptake, and the ability to cross the BBB via human TfR1-mediated transcytosis in newly generated humanized Tfr1h knock-in rats. To improve developability and reduce potential immunogenicity, selected TfR1b-Nbs were humanized and optimized with computational and artificial intelligence (AI) algorithms, enhancing humanness, solubility, and VHH-nativeness. Eight optimized TfR1b-Nbs retained BBB permeability and were fused to humanized anti-TNF nanobody inhibitors (TNFI- or TNFI-{beta}), generating 16 heterodimers. Fusion to these TNFIs served as a functional readout, confirming that TfR1b-Nbs can shuttle biologically active, BBB-impermeable payloads into the central nervous system (CNS). All heterodimers demonstrated CNS delivery after intravenous administration, and selected constructs also reached the brain via subcutaneous injection, maintaining high serum and cerebrospinal fluid (CSF) levels for up to 72 hours. A pilot study with one heterodimer showed that chronic administration in rats humanized for both transferrin and TfR1 caused no hematological toxicity or signs of anemia - a key safety concern when targeting TfR1. These results establish humanized TfR1b-Nbs - designated NewroBus - as promising BBB shuttles for the safe and effective therapeutic delivery of biologics to the brain.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Molecular Pharmaceutics
16 papers in training set
Top 0.1%
15.2%
2
Molecular Therapy
81 papers in training set
Top 0.2%
6.8%
3
Journal of Controlled Release
44 papers in training set
Top 0.2%
6.8%
4
PLOS ONE
5266 papers in training set
Top 28%
5.5%
5
Bioengineering & Translational Medicine
21 papers in training set
Top 0.1%
3.3%
6
Nature Communications
5641 papers in training set
Top 35%
3.3%
7
Frontiers in Immunology
638 papers in training set
Top 4%
3.3%
8
Cell Chemical Biology
94 papers in training set
Top 0.5%
2.4%
9
Advanced Science
286 papers in training set
Top 3%
2.4%
10
Fluids and Barriers of the CNS
28 papers in training set
Top 0.2%
1.9%
50% of probability mass above
11
Scientific Reports
3612 papers in training set
Top 53%
1.7%
12
International Journal of Molecular Sciences
494 papers in training set
Top 7%
1.7%
13
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.5%
1.7%
14
Biomaterials
84 papers in training set
Top 0.9%
1.7%
15
Science Advances
1243 papers in training set
Top 20%
1.7%
16
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.7%
1.5%
17
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 1%
1.4%
18
mAbs
32 papers in training set
Top 0.3%
1.3%
19
EMBO Molecular Medicine
95 papers in training set
Top 1%
1.3%
20
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 32%
1.3%
21
JCI Insight
277 papers in training set
Top 5%
1.3%
22
Journal of Experimental Medicine
119 papers in training set
Top 2%
1.3%
23
eLife
5828 papers in training set
Top 57%
1.1%
24
Advanced Therapeutics
17 papers in training set
Top 0.2%
1.1%
25
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.5%
1.1%
26
Science Translational Medicine
127 papers in training set
Top 2%
1.1%
27
Journal of Extracellular Vesicles
55 papers in training set
Top 0.5%
1.1%
28
Cell Reports Medicine
153 papers in training set
Top 4%
1.0%
29
ACS Omega
105 papers in training set
Top 3%
1.0%
30
The FASEB Journal
194 papers in training set
Top 5%
0.9%